

Grald Simonneau

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10380099/gerald-simonneau-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

331
papers

64,177
citations

110
h-index

252
g-index

350
ext. papers

75,872
ext. citations

10.2
avg, IF

7.2
L-index

#	Paper	IF	Citations
331	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for	9.5	3455
330	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009 , 30, 2493-537	9.5	2531
329	Bosentan therapy for pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2002 , 346, 896-903	59.2	2098
328	Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D34-41	15.1	1937
327	Sildenafil citrate therapy for pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2005 , 353, 2148-57	59.2	1843
326	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for	13.6	1672
325	European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Updated clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S43-S54	15.1	1640
324	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	1412
323	A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prvention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. <i>New England Journal of Medicine</i> , 1998 , 338, 409-15	59.2	1406
322	Pulmonary arterial hypertension in France: results from a national registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 1023-30	10.2	1367
321	Treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2004 , 351, 1425-36	59.2	1338
320	Inhaled iloprost for severe pulmonary hypertension. <i>New England Journal of Medicine</i> , 2002 , 347, 322-9	59.2	1308
319	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. <i>Lancet, The</i> , 2001 , 358, 1119-23	40	1175
318	Clinical classification of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 5S-12S	15.1	1162
317	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 780-8	15.1	1074
316	Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 800-4	10.2	1041
315	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. <i>Circulation</i> , 2010 , 122, 156-63	16.7	1035

314	Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. <i>New England Journal of Medicine</i> , 1996 , 335, 609-16	59.2	962
313	Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. <i>New England Journal of Medicine</i> , 1996 , 334, 682-7	59.2	941
312	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 809-18	59.2	878
311	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 319-29	59.2	852
310	New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. <i>Chest</i> , 2004 , 126, 1313-7	5.3	831
309	Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. <i>Circulation</i> , 2005 , 111, 3105-11	16.7	815
308	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , 2009 , 119, 2894-903	16.7	769
307	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004 , 25, 2243-78	9.5	665
306	Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. <i>Circulation</i> , 2011 , 124, 1973-81	16.7	630
305	A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. <i>New England Journal of Medicine</i> , 1997 , 337, 663-9	59.2	630
304	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015 , 373, 834-44	59.2	618
303	Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. <i>New England Journal of Medicine</i> , 2001 , 345, 325-34	59.2	579
302	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015 , 373, 2522-33	59.2	521
301	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 1496-502	15.1	478
300	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011 , 141, 702-10	1.5	454
299	Pulmonary arterial hypertension in patients treated by dasatinib. <i>Circulation</i> , 2012 , 125, 2128-37	16.7	448
298	Increased plasma serotonin in primary pulmonary hypertension. <i>American Journal of Medicine</i> , 1995 , 99, 249-54	2.4	445
297	Pulmonary hypertension due to left heart diseases. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D100-8	15.1	437

296	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. <i>Annals of Internal Medicine</i> , 2008 , 149, 521-30	8	437
295	Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. <i>Chest</i> , 2007 , 131, 1917-28	5.3	421
294	Chronic thromboembolic pulmonary hypertension. <i>Circulation</i> , 2006 , 113, 2011-20	16.7	413
293	Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2127-34	15.1	409
292	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2001 , 108, 1141-1150	15.9	391
291	Pulmonary hypertension in chronic lung diseases. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D109-16	15.1	390
290	Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. <i>Chest</i> , 2004 , 126, 35S-62S	5.3	382
289	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. <i>Circulation</i> , 2013 , 127, 1128-38	16.7	368
288	Ambrisentan therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 529-35	15.1	364
287	A hemodynamic study of pulmonary hypertension in sickle cell disease. <i>New England Journal of Medicine</i> , 2011 , 365, 44-53	59.2	354
286	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 81-8	10.2	336
285	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. <i>Circulation</i> , 2016 , 133, 859-71	16.7	331
284	Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. <i>Lancet, The</i> , 2002 , 360, 1914-20	40	330
283	Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 108-13	10.2	324
282	Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. <i>Human Mutation</i> , 2006 , 27, 121-32	4.7	322
281	Endothelial-to-mesenchymal transition in pulmonary hypertension. <i>Circulation</i> , 2015 , 131, 1006-18	16.7	320
280	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	298
279	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. <i>ACS Nano</i> , 2017 , 11, 112-125	16.7	279

278	Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1380-6	15.1	274
277	Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. <i>Arthritis and Rheumatism</i> , 2008 , 58, 521-31		261
276	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. <i>Nature Genetics</i> , 2014 , 46, 65-9	36.3	259
275	Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. <i>Chest</i> , 2006 , 130, 182-9	5.3	254
274	Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003 , 167, 1433-9	10.2	247
273	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 780-9	10.2	244
272	Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. <i>Gastroenterology</i> , 2006 , 130, 120-6	13.3	240
271	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. <i>Human Pathology</i> , 2007 , 38, 893-902	3.7	238
270	Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. <i>Anesthesiology</i> , 2005 , 102, 1133-7; discussion 5A-6A	4.3	234
269	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. <i>Medicine (United States)</i> , 2008 , 87, 220-233	1.8	229
268	Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1377-83	10.2	225
267	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2006 , 27, 589-95	9.5	224
266	Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. <i>New England Journal of Medicine</i> , 1981 , 304, 1582-5	59.2	223
265	Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. <i>Chest</i> , 2003 , 124, 247-54	5.3	221
264	Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. <i>Circulation</i> , 2006 , 113, 1857-64	16.7	217
263	CX(3)C chemokine fractalkine in pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 1419-25	10.2	216
262	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014 , 43, 1691-7	13.6	214
261	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. <i>Circulation</i> , 2014 , 130, 2189-208	16.7	209

260	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 851-61	10.2	209
259	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2012 , 40, 874-80	13.6	203
258	Chemokine RANTES in severe pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 534-9	10.2	202
257	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 129-37	35.1	202
256	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3522-30		199
255	Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 598-605	7	194
254	Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 1212-7	10.2	192
253	Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. <i>American Journal of Roentgenology</i> , 2004 , 183, 65-70	5.4	190
252	The pathophysiology of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Review</i> , 2017 , 26,	9.8	187
251	Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. <i>Chest</i> , 2011 , 140, 1274-1283	5.3	187
250	Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. <i>Chest</i> , 2004 , 126, 420-7	5.3	187
249	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). <i>European Respiratory Journal</i> , 2015 , 45, 1293-302	13.6	175
248	Portopulmonary hypertension: survival and prognostic factors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 637-43	10.2	175
247	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. <i>Human Mutation</i> , 2006 , 27, 212-3	4.7	173
246	Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1041-7	10.2	173
245	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 97	4.2	168
244	Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. <i>Circulation</i> , 2009 , 119, 1747-57	16.7	164
243	Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. <i>Circulation Research</i> , 2004 , 94, 1263-70	15.7	163

242	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. <i>Journal of Clinical Investigation</i> , 2009 , 119, 512-23	15.9	148
241	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 184, 116-23	10.2	147
240	Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. <i>Archives of Internal Medicine</i> , 2000 , 160, 159-64		145
239	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3207-18	15.9	144
238	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2010 , 31, 1898-907	9.5	139
237	Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. <i>American Journal of Medicine</i> , 1990 , 89, 117-20	2.4	139
236	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 177.e1-177.e62	1.5	137
235	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 81S-88S	15.1	137
234	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014 , 44, 1275-88	13.6	135
233	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016 , 47, 1518-34	13.6	134
232	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 785-794	35.1	133
231	Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1085-92	15.1	133
230	High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. <i>Chest</i> , 1999 , 116, 903-8	5.3	133
229	Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. <i>Clinics in Chest Medicine</i> , 2001 , 22, 451-8	5.3	132
228	Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 157, 1681-5	10.2	129
227	Targeted therapies in pulmonary arterial hypertension. <i>Pharmacology & Therapeutics</i> , 2014 , 141, 172-91	13.9	128
226	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. <i>Journal of Rheumatology</i> , 2007 , 34, 2417-22	4.1	128
225	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. <i>Aids</i> , 2010 , 24, 67-75	3.5	118

224	Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. <i>Medicine (United States)</i> , 2007 , 86, 299-315	1.8	118
223	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. <i>American Journal of Pathology</i> , 2015 , 185, 356-71	5.8	116
222	Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. <i>Chest</i> , 2004 , 126, 63S-71S	5.3	112
221	Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2007 , 26, 357-62	5.8	105
220	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011 , 8, 526-38	14.8	102
219	Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 668-80	15.1	101
218	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 768-74	15.1	101
217	New treatments for pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 1209-16	10.2	101
216	Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. <i>Chest</i> , 2009 , 136, 1211-1219	5.3	100
215	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016 , 133, 1371-85	16.7	98
214	Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011 , 45, 311-22	5.7	98
213	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 372-80	35.1	98
212	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1219-1227	2.4	96
211	Angiopietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 1025-33	10.2	95
210	Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2010 , 38, 277-84	3	94
209	Risk factors for pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , 2001 , 22, 459-75	5.3	94
208	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2015 , 47, e105-10	3	93
207	Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. <i>Annals of Thoracic Surgery</i> , 2012 , 94, 817-24	2.7	93

206	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018 , 137, 693-704	16.7	92
205	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1940-6	2.4	89
204	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2456-64		87
203	Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 1061-7	10.2	85
202	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 1727-36	13.6	85
201	Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. <i>Chest</i> , 2009 , 135, 760-768	5.3	83
200	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	82
199	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. <i>Nature Genetics</i> , 2013 , 45, 518-21	36.3	82
198	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. <i>Circulation</i> , 2015 , 132, 834-47	16.7	80
197	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 632-43	5.8	79
196	Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. <i>Chest</i> , 2012 , 142, 1150-1157	5.3	79
195	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2013 , 41, 224-32	13.6	78
194	Pulmonary veno-occlusive disease: recent progress and current challenges. <i>Respiratory Medicine</i> , 2010 , 104 Suppl 1, S23-32	4.6	78
193	Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 338-40	10.2	78
192	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 83-91	7	77
191	Primary pulmonary hypertension associated with the use of fenfluramine derivatives. <i>Chest</i> , 1998 , 114, 195S-199S	5.3	77
190	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 125-134	35.1	76
189	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2014 , 43, 915-7	13.6	76

188	Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 798-802	10.2	76
187	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013 , 41, 96-103	13.6	75
186	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009 , 26, 813-25	4.1	75
185	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	74
184	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. <i>Rheumatology</i> , 2010 , 49, 490-500	3.9	74
183	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 150-8	5.8	73
182	The CX3C chemokine fractalkine in allergic asthma and rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003 , 112, 1139-46	11.5	73
181	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 1366-75	5.8	72
180	Chronic thromboembolic pulmonary hypertension: role of medical therapy. <i>European Respiratory Journal</i> , 2013 , 41, 985-90	13.6	72
179	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	70
178	Key role of the endothelial TGF- β /ALK1/endothelin signaling pathway in humans and rodents pulmonary hypertension. <i>PLoS ONE</i> , 2014 , 9, e100310	3.7	67
177	Drug-induced pulmonary arterial hypertension: a recent outbreak. <i>European Respiratory Review</i> , 2013 , 22, 244-50	9.8	67
176	Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2007 , 49, 1-5	3.1	67
175	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014 , 44, 1627-34	13.6	66
174	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. <i>Respiratory Research</i> , 2010 , 11, 73	7.3	66
173	Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 608-14		65
172	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. <i>Respiratory Research</i> , 2011 , 12, 119	7.3	64
171	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 47, 541-52	13.6	63

170	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 717-726	35.1	62
169	Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015 , 46, 152-64	13.6	62
168	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	62
167	Pulmonary hypertension associated with benfluorex exposure. <i>European Respiratory Journal</i> , 2012 , 40, 1164-72	13.6	60
166	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	58
165	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. <i>European Respiratory Journal</i> , 2012 , 40, 630-40	13.6	58
164	Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. <i>Chest</i> , 1998 , 114, 50S-51S	5.3	56
163	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015 , 46, 1721-31	13.6	55
162	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. <i>European Respiratory Review</i> , 2013 , 22, 217-26	9.8	55
161	Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. <i>Chest</i> , 2007 , 131, 101-8	5.3	53
160	Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 1999 , 16, 38-43	3	52
159	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 752-763	15.1	50
158	The changing landscape of chronic thromboembolic pulmonary hypertension management. <i>European Respiratory Review</i> , 2017 , 26,	9.8	50
157	Future perspectives for the treatment of pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2009 , 54, S108-S117	15.1	50
156	BMP2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 1668-1681	13.6	49
155	Primary pulmonary hypertension: Current therapy. <i>Progress in Cardiovascular Diseases</i> , 2002 , 45, 115-28	8.5	48
154	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016 , 149, 353-361	5.3	46
153	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>American Heart Journal</i> , 2014 , 167, 210-7	4.9	46

152	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017 , 38, 1147-1155	9.5	44
151	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. <i>Rheumatology</i> , 2010 , 49, 940-4	3.9	44
150	Surgical management of unresolved pulmonary embolism. A personal series of 72 patients. <i>Chest</i> , 1995 , 107, 52S-55S	5.3	44
149	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <i>JACC: Heart Failure</i> , 2015 , 3, 1-8	7.9	42
148	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 189-96	10.2	42
147	Pulmonary hypertension in patients with neurofibromatosis type I. <i>Medicine (United States)</i> , 2011 , 90, 201-211	1.8	42
146	Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 607-18	1.6	42
145	Use of β Blockers in Pulmonary Hypertension. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	41
144	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017 , 65, 1683-1692	11.2	40
143	Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. <i>Chest</i> , 2012 , 142, 869-876	5.3	40
142	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , 2018 , 18, 37-47	4	39
141	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2012 , 40, 75-83	13.6	39
140	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. <i>Chest</i> , 2010 , 137, 1297-303	5.3	38
139	A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 756-9	10.2	37
138	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 894-901	35.1	37
137	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	37
136	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. <i>Chest</i> , 2017 , 151, 106-118	5.3	36
135	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. <i>Chest</i> , 2018 , 153, 143-151	5.3	35

134	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2014 , 15, 65	7.3	34
133	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014 , 172, 332-9	3.2	34
132	Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 601-7		34
131	Quality of life in patients with chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2016 , 48, 526-37	13.6	34
130	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. <i>European Respiratory Journal</i> , 2014 , 44, 1069-72	13.6	33
129	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 833-842	5.8	32
128	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019 , 139, 2440-2450	16.7	32
127	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015 , 94, e1800	1.8	32
126	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. <i>European Respiratory Journal</i> , 2012 , 39, 1534-5	13.6	32
125	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 596-605	2.4	32
124	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 647-655	5.8	31
123	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , 2016 , 47, 1436-44	13.6	31
122	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015 , 46, 1711-20	13.6	31
121	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 925-928	10.2	30
120	Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension. <i>Chest</i> , 2013 , 143, 1343-1350	5.3	30
119	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2013 , 22, 487-94	9.8	30
118	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16 Suppl 1, S11-9	3	30
117	Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2008 , 2, 249-65	4.9	30

116	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. <i>Oncotarget</i> , 2017 , 8, 52995-53016	3.3	30
115	Cardiopulmonary effects of a single oral dose of almitrine at rest and on exercise in patients with hypoxic chronic airflow obstruction. <i>Chest</i> , 1986 , 89, 174-9	5.3	29
114	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017 , 26,	9.8	28
113	Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 411-20	3.9	28
112	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , 2016 , 39, 287-94	5.1	26
111	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. <i>Chest</i> , 2015 , 147, 1385-1394	5.3	26
110	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , 2019 , 21, 352-359	12.3	26
109	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 1234-1242	5.8	25
108	Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. <i>Thrombosis Research</i> , 2007 , 120, 195-200	8.2	25
107	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , 2014 , 172, 561-7	3.2	24
106	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018 , 13, e0197112	3.7	24
105	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 1286-1295	5.8	22
104	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018 , 196, 157-164	2.9	22
103	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 151-161	15.4	22
102	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 573-584	35.1	22
101	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 872-881	5.3	22
100	Pulmonary veno-occlusive disease: the blue noire of pulmonary hypertension in connective tissue diseases?. <i>Presse Medicale</i> , 2011 , 40, e65-78	2.2	21
99	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. <i>Current Therapeutic Research</i> , 2002 , 63, 227-246	2.4	21

98	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. <i>Heart</i> , 2017 , 103, 599-606	5.1	19
97	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015 , 15, 13-26	4	19
96	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , 2020 , 39, 300-309	5.8	19
95	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1193-205	5.5	19
94	Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. <i>Respiration</i> , 2013 , 85, 471-7	3.7	19
93	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1585-96	4	19
92	Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. <i>Chest</i> , 2005 , 128, 622S	5.3	19
91	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. <i>Chest</i> , 2013 , 144, 1512-1520	5.3	18
90	Pulmonary arterial hypertension and its association with HIV infection: an overview. <i>Aids</i> , 2008 , 22 Suppl 3, S1-6	3.5	18
89	New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2113-31	4	17
88	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 216	3.5	17
87	Sildenafil for pulmonary arterial hypertension: still waiting for evidence. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 6-7	10.2	17
86	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018 , 13, e0193226	3.7	17
85	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2018 , 154, 521-531	5.3	17
84	Pulmonary arterial hypertension and HIV infection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 440-7	3.9	16
83	Treatments for severe pulmonary hypertension. <i>Lancet, The</i> , 1999 , 353, 338-40	40	16
82	Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , 2018 , 13, e0198198	3.7	16
81	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1393-1403	15.1	16

80	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 404-411	2.7	15
79	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 1102-1110	5.8	15
78	Chronic thromboembolic pulmonary hypertension. <i>Presse Medicale</i> , 2015 , 44, e409-16	2.2	15
77	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	15
76	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. <i>Journal of Cardiac Failure</i> , 2017 , 23, 29-35	3.3	14
75	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 689-97	5.8	14
74	The study of risk in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012 , 21, 234-8	9.8	14
73	Future perspectives in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2016 , 25, 381-389	9.8	14
72	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. <i>Respiratory Medicine</i> , 2017 , 122 Suppl 1, S18-S22	4.6	13
71	Riociguat for pulmonary hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 2268	59.2	13
70	Serotonin transporter and receptors in various forms of human pulmonary hypertension. <i>Chest</i> , 2005 , 128, 552S-553S	5.3	13
69	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. <i>Nature Clinical Practice Rheumatology</i> , 2005 , 1, 93-101		13
68	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 842-854	10.2	13
67	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	12
66	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 401-408	5.8	12
65	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2017 , 36, 386-398	5.8	12
64	Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure. <i>Respiration</i> , 2013 , 85, 464-70	3.7	12
63	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1337-48	4	12

62	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 348-55	5.8	11
61	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	11
60	Screening for pulmonary arterial hypertension in adults carrying a mutation. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	11
59	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020 , 63, 118-131	5.7	11
58	Vasodilators in patients with chronic obstructive pulmonary disease and pulmonary hypertension: not ready for prime time!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 202-3	10.2	10
57	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021 , 178, 106220	4.6	10
56	A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1457-65	2.4	9
55	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2010 , 104 Suppl 1, S74-80	4.6	9
54	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. <i>European Respiratory Journal</i> , 2012 , 39, 1549-50	13.6	9
53	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16 Suppl 1, S43-6	3	9
52	The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. <i>PLoS ONE</i> , 2013 , 8, e77073	3.7	9
51	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. <i>ERJ Open Research</i> , 2021 , 7,	3.5	9
50	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 194-202	5.8	9
49	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	8
48	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , 2018 , 95, 244-250	3.7	7
47	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018 , 154, 882-892	5.3	7
46	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2014 , 8, 84-92	4.9	7
45	Pulse wave reflection in pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 743-4	15.1	7

44	Snoring and Obstructive Sleep Apnea: Objective Efficacy and Impact of a Chairside Fabricated Mandibular Advancement Device. <i>Journal of Prosthodontics</i> , 2017 , 26, 381-386	3.9	6
43	Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?. <i>Annals of the American Thoracic Society</i> , 2016 , 13 Suppl 3, S255-8	4.7	6
42	Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. <i>Chest</i> , 2011 , 140, 1066-1068	5.3	6
41	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 647-56	5.8	6
40	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005095	5.8	5
39	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 1469-76	3.8	5
38	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 537-541	10.2	5
37	Survival Improved in Patients Aged \geq 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. <i>Chest</i> , 2020 , 157, 945-954	5.3	5
36	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 843-852	10.2	4
35	The French registry of pulmonary arterial hypertension in children: rationale and design. <i>Current Medical Research and Opinion</i> , 2007 , 23, S27-S33	2.5	4
34	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. <i>European Respiratory Journal</i> , 2021 ,	13.6	4
33	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2020 , 177, 106241	4.6	4
32	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , 2021 , 160, 277-286	5.3	4
31	Safety of therapeutic doses of tinzaparin during pregnancy. <i>Gynecologic and Obstetric Investigation</i> , 2015 , 79, 256-62	2.5	3
30	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. <i>Journal of Clinical Monitoring and Computing</i> , 2017 , 31, 903-910	2	3
29	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2015 , 46, 1211-4	13.6	3
28	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". <i>Circulation</i> , 2015 , 132, e154	16.7	3
27	Reply: pulmonary hypertension of sickle cell disease beyond classification constraints. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2882-3	15.1	3

26	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation	9.5	3
25	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , 2009 , 62, 1464.e1-1464.e58	1.5	3
24	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16 Suppl 1, S21-6	3	3
23	New Formula for Predicting Mean Pulmonary Artery Pressure. <i>Chest</i> , 2005 , 128, 467	5.3	3
22	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology.. <i>Annals of Cardiothoracic Surgery</i> , 2022 , 11, 106-119	4.7	3
21	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	3
20	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. <i>European Respiratory Review</i> , 2014 , 23, 260-3	9.8	2
19	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020973124	2.7	2
18	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2021 , 177, 106293	4.6	2
17	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021 , 21, 3388-3400	8.7	2
16	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009 , 62, 1464.e1-1464.e58	0.7	1
15	The Need for National Registries in Rare Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 228a-229	10.2	1
14	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1133-8	4	1
13	Embolie pulmonaire : histoire naturelle, diagnostic, traitement. <i>Encyclopédie Médico-chirurgicale Pneumologie</i> , 2004 , 1, 1-8		1
12	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. <i>Pulmonary Circulation</i> , 2019 , 2045894019837849	2.7	1
11	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1009-1018	5.8	1
10	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience.. <i>Annals of Cardiothoracic Surgery</i> , 2022 , 11, 143-150	4.7	1
9	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1306-1315	4.7	0

- 8 Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1172-1180 5.8 0
- 7 Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1364-1365 19.2
- 6 Classification de l'hypertension pulmonaire. *Archives of Cardiovascular Diseases Supplements*, **2010**, 2, 132-136 0.3
- 5 Updated Clinical Classification of Pulmonary Hypertension. *Progress in Respiratory Research*, **2012**, 1-13
- 4 Pulmonary Hypertension in Sickle Cell Disease. *Progress in Respiratory Research*, **2012**, 137-142
- 3 Bosentan in mild pulmonary hypertension [Authors' reply]. *Lancet, The*, **2008**, 372, 1731-1732 4.0
- 2 Pulmonary hypertension associated with portal hypertension **2011**, 245-250
- 1 Pulmonary hypertension related to appetite suppressants **2011**, 236-244